FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 06/2025”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of June 2025 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 19,813m.
- This represents a 5% decline of the funding volume vs. last year continuing the negative trend for Healthcare and Life Sciences funding in the USA in 2025
- Biotech/Pharma received 44% of the total investment volume (EUR 8,766m) with oncology being the leading indication (26%)
- In June, Dispatch Biotherapeutics secured the highest transaction volume with EUR 189m, followed by Athelas with EUR 175m and Commure with EUR 175m
- Subsequently, a mega-financing deal worth the equivalent of USD 1 billion was announced in January for Retro, a biotech company conducting research in the field of the central nervous system
- General Catalyst (United States) is the most active investor (by deal volume in 2025), followed by Illumina (United States) and ARCH Venture Partners (United States)
To access the full report, please click here.
By Mathias Klozenbücher und Johannes Link
#FCF #Healthcare #Life #Sciences #Venture #Capital #Monitor #USA #published
